These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23620452)

  • 1. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
    Zinzani PL; Pellegrini C; Derenzini E; Argnani L; Pileri S
    Hematol Oncol; 2013 Dec; 31(4):223-4. PubMed ID: 23620452
    [No Abstract]   [Full Text] [Related]  

  • 2. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
    Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous transplantation and management of younger patients with mantle cell lymphoma.
    Geisler CH
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
    J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
    Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
    Gyan E; Damotte D; Courby S; Sénécal D; Quittet P; Schmidt-Tanguy A; Banos A; Le Gouill S; Lamy T; Fontan J; Maisonneuve H; Alexis M; Dreyfus F; Tournilhac O; Laribi K; Solal-Céligny P; Arakelyan N; Cartron G; Gressin R;
    Br J Haematol; 2013 Jul; 162(2):240-9. PubMed ID: 23692641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy in diffuse large B-cell lymphoma.
    Michallet AS; Lebras L; Coiffier B
    Curr Opin Oncol; 2012 Sep; 24(5):461-5. PubMed ID: 22759738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
    Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
    Tarella C; Zanni M; Di Nicola M; Patti C; Calvi R; Pescarollo A; Zoli V; Fornari A; Novero D; Cabras A; Stella M; Comino A; Remotti D; Ponzoni M; Caracciolo D; Ladetto M; Magni M; Devizzi L; Rosato R; Boccadoro M; Bregni M; Corradini P; Gallamini A; Majolino I; Mirto S; Gianni AM;
    Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who should receive myeloablative therapy for diffuse large B-cell lymphoma?
    Wannesson L; Zucca E
    Nat Clin Pract Oncol; 2008 Aug; 5(8):442-3. PubMed ID: 18607392
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
    Krawczyk K; Jurczak W; Gałązka K; Gruchała A; Skotnicki AB
    J Med Case Rep; 2014 Oct; 8():325. PubMed ID: 25277681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
    Zinzani PL; Pellegrini C; Argnani L; Broccoli A
    Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.